Sep 3, 2021 This Week in Cardiology Podcast
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 3 September 2021
⏱️ 25 minutes
🧾️ Download transcript
Summary
EMPEROR-Preserved, the LOOP study, ablate-and-pace for AF, and salt substitute and stroke: John Mandrola, MD provides a first of two ESC reviews. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
1 - HFpEF
- EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
- Empagliflozin and Major Renal Outcomes in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMc2112411
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
2 - AF Screening
- LOOP Trial Undercuts Value of Long-term Continuous ECG Screening for Atrial Fibrillation https://www.medscape.com/viewarticle/957473
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext
- Subclinical Atrial Fibrillation and the Risk of Stroke https://www.nejm.org/doi/full/10.1056/nejmoa1105575
3 - Ablate and Pace for AF and HF
- APAF-CRT: 'Ablate and Pace' Cuts Mortality in Narrow-QRS HF, Permanent AF https://www.medscape.com/viewarticle/957467
- A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS https://academic.oup.com/eurheartj/article/39/45/3999/5078460
- AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial https://doi.org/10.1093/eurheartj/ehab569
4 - Salt Substitute and Stroke
- Salt Substitute Shows Clear Reduction in Stroke, CV Events, and Death https://www.medscape.com/viewarticle/957472
- Effect of Salt Substitution on Cardiovascular Events and Death https://www.nejm.org/doi/full/10.1056/NEJMoa2105675
Features:
- Incremental, Not Monumental, Win for Empagliflozin in Heart Failure With Preserved Ejection Fraction https://www.medscape.com/viewarticle/957465
- Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context https://www.medscape.com/viewarticle/957388
- Lessons on AF Screening From the LOOP Study https://www.medscape.com/viewarticle/957512
- Ablate-and-Pace Delivers a Huge Win for Those Sick With AF https://www.medscape.com/viewarticle/958033
- Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics? https://www.medscape.com/viewarticle/957510
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to this week in cardiology from the heart.org on medscape. |
| 0:09.7 | You can now access the latest in medical news on your Amazon Alexa enabled device. |
| 0:14.3 | Join me, Perry Wilson, every weekday morning for Medscape Medical Minute, where I highlight |
| 0:18.8 | the top medical stories of the day. |
| 0:21.1 | To add Medscape Medical Minute to your flash briefing, search for Medscape Medical |
| 0:24.7 | Minute on Amazon and click enable. Or open the Amazon Alexa app, go to Skills, search for Medscape Medical |
| 0:31.0 | Minute and click enable. Then say, |
| 0:33.4 | Alexa, what's the news or Alexa, what's my flash briefing? I hope you'll join us. |
| 0:40.6 | Hi everyone, this is John Mandrola from the Heart.org Medscape |
| 0:44.8 | Cardiology and this is this week in Cardiology for September 3rd 2021. This |
| 0:52.0 | week will be a European Society of Cardiology Meeting wrap-up. |
| 0:57.0 | I'll probably take two to three weeks to get through all of the studies at ESC. |
| 1:02.0 | First, COVID, I'm not saying a word about COVID today. Let's just move to |
| 1:08.1 | cardiology. The first is of course Emperor Preserved. |
| 1:13.0 | This was Empaglof-Losen versus placebo in heart failure with a preserved ejection fraction. |
| 1:19.0 | The SGLT2 inhibitors have been proven beneficial for the reduction of CV events in type 2 diabetes, |
| 1:27.0 | the reduction in renal outcomes and chronic kidney disease, |
| 1:31.0 | and a reduction of heart failure hospitalizations and CV death in heart failure with reduced |
| 1:35.8 | dejection fraction. |
| 1:38.0 | Emperor Preserved was the first randomized controlled trial testing SGLT two inhibitors, |
| 1:44.1 | Impa glyphlosing, in patients with heart failure |
| 1:46.9 | with preserved ejection fraction. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.